Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin-like growth factor 1 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
Insulin-like growth factor 1 (IGF-1) small interfering RNA is a therapeutic modality designed to silence the expression of the IGF-1 gene through the RNA interference (RNAi) pathway. By targeting the mRNA transcript of IGF-1, these siRNAs trigger its degradation, thereby reducing the production of the IGF-1 protein. IGF-1 is a potent growth factor involved in cell proliferation, survival, and transformation, and its dysregulation is implicated in various cancers (such as acute myeloid leukemia, prostate, and breast cancer) as well as growth disorders like acromegaly. In the context of oncology, IGF-1 signaling often promotes constitutive activation of the PI3K/Akt pathway, contributing to tumor growth and resistance to therapy. While widely utilized as a research tool to study the IGF-1/IGF-1R signaling axis, specific clinical-stage assets are typically identified by sponsor-specific codes.
- Other names
- IGF-1 siRNAIGF1 siRNAIGF 1 siRNAsiRNA targeting IGF-1
02
Targets
IGF-1 (Insulin-like growth factor 1)
Beyond the preview
Go deeper on insulin-like growth factor 1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin-like growth factor 1 small interfering RNA.